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Background: Preeclampsia reduces placental expression and activity of 11β-hydroxysteroid dehydrogenase type 2
(HSD11B2), leading to an increase in fetal glucocordicoids. The latter has been proposed to be associated with low
birth weight and high risk of metabolic diseases in later life of the offspring. This investigation aims to delineate the
alteration in methylation levels at CpG sites of HSD11B2 promoter.
Results: Methylation levels of HSD9-2, HSD9-3, HSD23-2 and HSD23-3 and the mean methylation level were
significantly lower in preeclampsia than in normal pregnancy (P = 0.002, 0.031, 0.047 and 0.001, respectively and
P < 0.001 in mean). The mean methylation level was significantly correlated with preeclampsia after the adjustment
of birth weight, maternal age, gestational age at delivery and fetal gender (r = 0.325, P < 0.001).
Conclusions: Preeclampsia reduced methylation level at fetal HSD11B2 promoter. A positive correlation existed
between HSD11B2 promoter methylation and preeclampsia. Our findings suggest that the methyaltion status of
HSD11B2 promoter is a potentially accessible biomarker for preeclampsia. However, further studies are required to
address the mechanisms of thehypomethylation at HSD11B2 promoter and the significance of the hypomethylation
in the development of metabolic diseases of the fetals born to preeclamptic women.
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Preeclampsia is a pregnancy-specific disease characterized
by de-novo development of concurrent hypertension and
proteinuria and sometimes progresses into a multiorgan
cluster of varying clinical features. Complicating 2-8% of
pregnancies, preeclampsia remains a leading cause of
maternal and perinatal mortality and morbidity [1]. Fur-
thermore, offspring of preeclamptic pregnancies are at the
high risk of metabolic diseases in late life.
Worldwide, association studies between low birth weight
and the subsequent development of common cardiovascu-
lar and metabolic disorders, including hypertension, insulin
resistance, type 2 diabetes and cardiovascular disease death
have been observed [2-4]. Relatively low birth weight is
one of the characteristics of preeclampsia. Intrauterine* Correspondence: huanghefg@hotmail.com
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unless otherwise stated.exposure to excessive glucocordicoids has been demon-
strated to be one of the mechanisms leading to low birth
weight. On the other hand, reduced placental expression
and activity of 11β-hydroxysteroid dehydrogenase type 2
(HSD11B2) which controls cellular concentration and the
transmission of cortisol from the mother to the fetus have
been documented in preeclampsia, which subsequently
leads to the increased fetal glucocordicoids. The later
phenomenon has been considered to be one of the mecha-
nisms programming fetal risk of metabolic diseases in
adulthood.
Animal models have suggested that methylation plays
a critical role in placenta development, and alterations
to its methylation pattern can lead to adverse placenta
morphology and birth outcome [5]. In humans, the
methylation status of promoter controls the gene expres-
sion and altered methylation levels at imprinted genes
have been reported to be one of the mechanisms leading
to increased risk of metabolic diseases in the offspring of
preeclampsia [6]. However, few researches are availableThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics and average methylation levels of
study population
Normal pregnancy Preeclampsia P value
TOTAL N 78 43
Maternal age (y) 28.56 ± 3.36 31.67 ± 4.68 0.356
Gestational age (y) 38.77 ± 1.40 36.11 ± 3.16 2.904
Birth weigh (g) 3287.82 ± 393.30 2626.98 ± 860.60 0.014
HSD9_CpG_1 0.13 ± 0.027 0.12 ± 0.031 0.279
HSD9_CpG_2 0.10 ± 0.019 0.09 ± 0.018 0.002
HSD9_CpG_3 0.41 ± 0.048 0.39 ± 0.056 0.031
HSD9 0.22 ± 0.026 0.21 ± 0.030 0.053
HSD23_CpG_1 0.16 ± 0.036 0.16 ± 0.036 0.789
HSD23_CpG_2 0.17 ± 0.096 0.13 ± 0.031 0.047
HSD23_CpG_3 0.15 ± 0.064 0.11 ± 0.048 0.001
HSD23 0.16 ± 0.051 0.13 ± 0.029 0.007
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promoter of HSD11B2 in the offspring of preeclamptic
women.
The aims of this investigation were to clarify fetal
methylation status at CpG sites of the promoter of
HSD11B2 in preeclampsia and normal pregnancy, and
discuss the possible role of alteration in methylation at
the promoter of HSD11B2 in programming of the risk of




Forty-three women of preeclampsia (25 of mild and 18
of severe) and 78 normal pregnant women were recruited
in Women’s Hospital, School of Medicine, Zhejiang
University. The diagnosis of preeclampsia including severe
preeclampsia and mild preeclampsia was defined as the
previous study [7-9].
The control women had no sign of gestational com-
plications and fetal distress and gave birth to healthy
neonates of appropriate size for gestational age. All the
participants are Han Chinese in origin.
The protocol of current investigation was approved by
the Ethics Committee of Women’s Hospital, School of
Medicine, Zhejiang University and informed consents
were obtained from all the participants.
DNA methylation analysis
Umbilical cord blood samples were collected in Ethylene
Diamine Tetraacetic Acid (EDTA)-treated tubes at delivery
for subsequent DNA extraction. Genomic DNA was
isolated using the QIAamp DNA Blood Mini Kit following
the standard protocol (QIAGEN, Hilden, Germany) and
Thermo NanoDrop2000 (Thermo, Wilmington, USA) was
used to detect 260/280 nm UV absorbance ratio and con-
centration. Bisulfite conversion of DNA was carried out
using the Epitect Bisulfite Kit (QIAGEN, Hilden, Germany).
Quantitative methylation analysis of DNA was perfor-
med using MassARRAY EpiTYPER assays (Sequenom,






AAAACAAAAA-3′ were designed using Epidesigner
(Sequenom, San Diego, CA; http://www.epidesigner.com).
Polymerase chain reaction (PCR) amplification was per-
formed using a 5 μl reaction mixture with the following
procedure: initial denaturation at 94°C for 4 min, followed
by 40 cycles of 95°C for 25 sec, 58°C for 25 sec, 72°C for
70 sec and a final extension at 72°C for 7 min. The PCR
products were then incubated with shrimp alkalinephosphatase (SAP, Sequenom, San Diego, CA) at 37°C for
20 min, followed by heat inactivation at 85°C for 5 min.
Transcription reactions were followed according to the
manufacturer’s standard protocol using T-cleavage assay
kit (Sequenom, San Diego, CA). 20 μl H2O and 6 mg of
Clean Resin (Sequenom, San Diego, CA) were added to
the transcription products to remove bilvalent cation
adducts. The samples were then sequenced on a MassAR-
RAY analyzer (Sequenom, San Diego, CA) and analyzed
with EpiTyper software (Sequenom, San Diego, CA). The
amplicon comprised 6 CpG sites at the HSD11B2 DMR
in Human Genome 19 assembly - Chr16: 67,462,267–
67,462,481 and 67,464,230–67,464,394 (GRCh37/hg19),
CpG site 1: 67,462,292; CpG site 2: 67,462,330; CpG site 3:
64,762,387; CpG site 4: 67,464,331; CpG site 5: 67,464,368;
CpG site 6: 67,464,389.
Statistical analysis
The Kolmogorov-Smirnov tests were used to evaluate
the distribution of data. Student t-tests were used for the
comparison of continuous data between groups. Chi-
square test was used for the analysis of categorical data.
Linear mixed model analysis was used for the relation-
ship of methylation level with the presence of pre-
eclampsia, birth weight, maternal age, gestational age at
delivery and fetal gender. Multivariate linear regression
was used to evaluate the correlation of mean methyla-
tion level with birth weight, maternal age, gestational
age at delivery and fetal gender. SPSS statistical package
(Statistical Analysis System, Chicago, IL) was used for
the data analysis. Values of P < 0.05 were considered to
be statistically significant.
Results
As shown in Table 1, no significant differences between
preeclamptic and control pregnancies were observed
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difference in gestational age at delivery. The neonatal
birth weights were significantly lower in differences in
preeclampsia than normal pregnancy.
The methylation levels were detected at 6 CpG sites of
HSD11B2 promoter. There were no significant differ-
ences at any of these 6 CpG sites between male and
female infants in either normal pregnancy (P > 0.05 for all)
(Table 2) or preeclampsia (P > 0.05 for all) (Table 1). Then,
data of male and female infants were pooled. The methy-
lation levels at sites HSD9-2, HSD9-3, HSD23-2 and
HSD23-3 of HSD promoter were significantly lower in
preeclampsia than in normal pregnancy (P = 0.002, 0.031,
0.047 and 0.001, respectively) (Figure 1), but the methyla-
tion levels at site HSD9-1 and HSD23-1 did not signifi-
cantly differ (P = 0.279 and 0.789, respectively, Table 2)
(Figure 2). The methylation levels of HSD11B2 promoter
were not significantly different between mild and severe
preeclampsia (P > 0.05 for all, Table 3).
The mean methylation levels at the HSD11B2 pro-
moter were significantly different between normal preg-
nancy and preeclampsia (P = 0.007, Table 1). The mean
methylation level was significantly lower in preeclampsia
than normal pregnancy (P < 0.001). There was no signifi-
cant difference in mean methylation level between mild
and severe preeclampsia (P = 0.672) (Figure 2).
The mean methylation level was significantly corre-
lated with preeclampsia after birth weight, maternal age,
gestational age at delivery and fetal gender were adjusted
(r = 0.325, P < 0.001), but not significantly correlated
with birth weight (P = 0.165), maternal age (P = 0.778),
gestational age at delivery (P = 0.064) and fetal gender
(P = 0.801).
Discussion
HSD11B2 is abundantly expressed in placenta and
controls intracellular concentration of cortisol as well as
the transition of cortisol from the mother to the fetus.
Placental expression and activity of HSD11B2 is reducedTable 2 Average methylation levels of HSD between male an
Gender of neonater Normal pregnancy
Male Female
TOTAL N 40 38
HSD9_CpG_1 0.13 ± 0.032 0.13 ± 0.023
HSD9_CpG_2 0.10 ± 0.022 0.11 ± 0.016
HSD9_CpG_3 0.40 ± 0.047 0.42 ± 0.048
HSD9 0.21 ± 0.030 0.22 ± 0.020
HSD23_CpG_1 0.16 ± 0.035 0.15 ± 0.036
HSD23_CpG_2 0.16 ± 0.092 0.17 ± 0.101
HSD23_CpG_3 0.15 ± 0.060 0.15 ± 0.070
HSD23 0.16 ± 0.045 0.16 ± 0.057in preeclampsia with comparison to normal pregnancy
[8,9]. Diminished 11b-HSD11B22 activity which allows
for more than 10-20% passage of maternal gluco-
corticoids leads to increased fetal blood cortisol levels in
preeclampsia [10-12]. Glucocorticoids, such as cortisol
and corticosterone control fetal and pre- and postnatal
development evolving the term glucocorticoid program-
ming. This is thought to affect the brain, the hypothal-
amic–pituitary axis, the blood pressure regulatory systems,
the heart, glucose-insulin homeostasis and metabolism, the
pancreas and fat tissue [13,14]. Increased level of fetal
glucocorticoids has been associated with low birth weight
and subsequent increased risk of metabolic diseases in
adulthood in humans and animal models [15-18].
During development, 11b-HSD11B2 is highly expressed
in fetal tissues including kidney, lung, gut and notably
brain [19-21]. However, the alteration in fetal HSD11B2
expression and activity has never been delineated yet in
preeclampsia. In this investigation, we revealed for the
first time the reduced fetal methylation at CpG sites of
HSD11B2 promoter in preeclampsia, implying the ex-
pression of HSD11B2 is likely to be increased. Although
it was reported that HSD11B2 was expressed in fetal
kidney in human from early gestation, the expression
and activity of HSD11B2 were determined in neither
fetal kidney nor other tissues at birth. Unpublished data
from our laboratory showed the expression of HSD11B2
in fetal kidney of X-induced preeclampsia model is de-
creased, whereas intrauterine growth restriction (IUGR)
increased the methylation at CpG sites of HSD11B2
promoter in animal model. Those findings imply the
complexity in the effects of pregnancy complications on
fetal HSD11B2 expression and activity.
Interestingly, our present finding of a hypomethylation
level at fetal HSD11B2 promoter in preeclampsia is not
consistent with findings from other published studies in
this area. Zhao et al. [22] found methylation levels of all
studied HSD11B2 gene promoter were significantly higher
in IUGR newborns. Several methodological differencesd female infants
P value Preeclampsia P value
Male Female
22 21
0.943 0.12 ± 0.025 0.12 ± 0.037 0.989
0.358 0.09 ± 0.020 0.10 ± 0.016 0.248
0.087 0.38 ± 0.063 0.40 ± 0.047 0.481
0.341 0.20 ± 0.030 0.21 ± 0.030 0.324
0.103 0.16 ± 0.034 0.15 ± 0.038 0.417
0.953 0.14 ± 0.032 0.13 ± 0.032 0.498
0.839 0.12 ± 0.056 0.10 ± 0.038 0.235
0.749 0.14 ± 0.030 0.13 ± 0.030 0.190
Figure 1 Average methylation levels of HSD in both normal pregancy group and preeclampsia group. There is significant differences of
average methylation levels between normal pregance and preeclampsia group in HSD23_CpG2, HSD23_CpG3 and HSD23 (*P < 0.05). Data are
shown as mean ± SD.
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studies. We conducted a study among 43 women of
preeclampsia with healthy newborn, and we took um-
bilical cord blood for sample. Zhao et al. employed
an experimental design with 22 IUGR newborns and
used pooled sample from placenta. Moreover, CpG
sites in the HSD11B2 promoter regions of our sample
are not the same as those of Zhao et al. As this is an emer-
ging area of research, more work is needed to better
characterize the association of preeclampsia and HSD11B2
methylation.
Numerous mechanisms have been described to control
11b-HSD2 expression and activity. Conditions comprom-
ise HSD11B2 expression and activity including enhanced
availability of pro-inflammatory cytokines (TNF-a, IL-1b
and Il-6), enhanced shear stress via focal adhesions and
hypoxia [23-26]. Hypoxia compromises the up-regulationFigure 2 Comparison of methylation level between mild and
severe preeclampsia. There was no significant difference in mean
methylation level between mild and severe preeclampsia (P = 0.563).
Data are shown as mean ± SD.of HSD11B2 during the differentiation of cytotrophoblasts
into syncytiotrophoblasts. These conditions were pre-
sent in the placenta and fetus of preeclampsia. Epigenetic
modification Methylation at CpG sites of promoter is one
of the epigenetic mechanisms regulating the gene ex-
pression. DNA methylation is among the best studied
epigenetic modifications and the methylation of cyto-
sine at CpG dinucleotides is an important regulatory
modification of genome. Other regulatory mechanisms
include transcriptional regulation and posttranscriptional
modification.
Generally, the low methylation at CpG sites of pro-
moter results in high expression of the gene. However, a
partial deficit in the activity of the enzyme 11b-HSD2
was observed in essential hypertensive patients [27] and a
significantly lower level messenger RNA for HSD11B2
was found in the hypertensive patients [28]. In addition,Table 3 Average methylation levels of HSD in both mild
and severe preeclampsia group
Gender of
neonater
Mild preeclampsia Severe preeclampsia P value
TOTAL N 25 18
HSD9_CpG_1 0.12 ± 0.022 0.13 ± 0.041 0.626
HSD9_CpG_2 0.093 ± 0.016 0.089 ± 0.022 0.505
HSD9_CpG_3 0.400 ± 0.044 0.38 ± 0.067 0.152
HSD9 0.21 ± 0.024 0.20 ± 0.037 0.690
HSD23_CpG_1 0.16 ± 0.034 0.15 ± 0.040 0.753
HSD23_CpG_2 0.13 ± 0.032 0.14 ± 0.030 0.193
HSD23_CpG_3 0.11 ± 0.049 0.11 ± 0.048 0.818
HSD23 0.13 ± 0.028 0.14 ± 0.031 0.672
Hu et al. BMC Genetics 2014, 15:96 Page 5 of 6
http://www.biomedcentral.com/1471-2156/15/96Friso et al. [29] found that elevated HSD11B2 promoter
methylation was associated with hypertension develop-
ing in glucocorticoid-treated patients and essential
hypertension. Taken these observations together with
our findings, it is implied that hypomethylation status
at the promoter of HSD11B2 may not be among the
mechanisms linking intrauterine exposure to maternal
preeclampsia and high risk of metabolic diseases in
adulthood.
Abnormal hypermethylated or hypomethylated genes
can serve as biomarkers for clinical use in early detection,
classification, and prediction of treatment response. In our
study, we detected the alteration in methylation status at
the promoter of HSD11B2 in the offspring of pre-
eclamptic women. We finally found that methylation
levels of HSD11B2 promoter were significantly lower in
preeclampsia than normal pregnancy. The positive rela-
tionship between HSD11B2 promoter methylation and
infants born to preeclamptic women with the hypo-
methylated HSD11B2 may be a potential marker for
preeclampsia. However, further studies are required to
address the mechanisms leading fetal hypomethylation
at HSD11B2 promoter and the significance of the hypo-
methylation in the development of metabolic diseases.
Conclusions
In conclusion, our study suggests that the decreased
methylation at the promoter of HSD in the fetuses of
preeclamptic women could be a potentially accessible
biomarker for preeclampsia women. Further studies are
required to explain the mechanisms of hypomethylation
at HSD11B2 promoter in infants born to preeclamptic
women.
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